1. Generics Bulletin
  2. >>Business
  3. >>Deals

Panaxia And Neuraxpharm Sign To Sell Medical Cannabis In The Czech Republic And Switzerland

The Companies Have Already Partnered In Germany, France, And Poland

 
• By Rosalind Rei

Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.

Cannabis leaf against detail of flag of the Czech Republic
Czech law is becoming more favourable to medical cannabis prescription • Source: Shutterstock

Neuraxpharm and Panaxia have signed two addendums to an existing agreement that will allow the partners to market medical cannabis in the Czech and Swiss markets.

Israeli firm Panaxia – a global specialist in pharmaceutical-quality cannabis products – will manage the manufacturing of pharmaceutical-grade medical cannabis premium oils and extracts for inhalation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.